Enhanced oral bioavailability of acyclovir by inclusion complex using hydroxypropyl-β-cyclodextrin

References

• Arnal J, Gonzalez-Alvarez I, Bermejo M, et al. (2008). Biowaiver monographs for immediate release solid oral dosage forms: aciclovir. J Pharm Sci 97:5061–73
   PubMed Web of Science ®Google Scholar
• Attia IA, El-Gizawy SA, Fouda MA, Donia AM. (2007). Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS Pharm Sci Tech 8:206--12
   Web of Science ®Google Scholar
• Bergstrom CA, Strafford M, Lazorova L, et al. (2003). Absorption classification of oral drugs based on molecular surface properties. J Med Chem 46:558–70
   PubMed Web of Science ®Google Scholar
• Calderón L, Harris R, Cordoba-Diaz M, et al. (2013). Nano and microparticulate chitosan-based systems for antiviral topical delivery. Eur J Pharm Sci 48:216–22
   PubMed Web of Science ®Google Scholar
• Carrier RL, Miller LA, Ahmed I. (2007). The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 123:78–99
   PubMed Web of Science ®Google Scholar
• Castro-Hermida JA, Gómez-Couso H, Ares-Mazás ME, et al. (2004). Anticryptosporidial activity of furan derivative G1 and its inclusion complex with beta-cyclodextrin. J Pharm Sci 93:197–206
   PubMed Web of Science ®Google Scholar
• Challa R, Ahuja A, Ali J, Khar RK. (2005). Cyclodextrins in drug delivery: an updated review. AAPS Pharm Sci Tech 6:E329–57
   PubMed Web of Science ®Google Scholar
• Cortesi R, Esposito E. (2008). Acyclovir delivery systems. Expert Opin Drug Deliv 5:1217–30
   PubMed Web of Science ®Google Scholar
• De Clercq E, Field HJ. (2006). Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 147:1–11
   PubMed Web of Science ®Google Scholar
• Fasinu P, Pillay V, Ndesendo VM, et al. (2013). Diverse approaches for the enhancement of oral drug bioavailability. Biopharm Drug Dispos 32:185–209
   Web of Science ®Google Scholar
• Fletcher C, Bean B. (1985). Evaluation of oral acyclovir therapy. Drug Intell Clin Pharm 19:518–24
   PubMedGoogle Scholar
• Friedrichsen GM, Chen W, Begtrup M, et al. (2002). Synthesis of analogs of L-valaciclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells. Eur J Pharm Sci 16:1–13
   PubMed Web of Science ®Google Scholar
• Higuchi T, Connors KA. (1965). Phase solubility techniques. Adv Anal Chem Instr 4:117–212
   Google Scholar
• Irie T, Uekama K. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 86:147–62
   PubMed Web of Science ®Google Scholar
• Jain SK, Jain RK, Chourasia MK, et al. (2005). Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium. AAPS Pharm Sci Tech 6:E35–41
   PubMed Web of Science ®Google Scholar
• Johnson GL, Limon L, Trikha G, Wall H. (1994). Acute renal failure and neurotoxicity following oral acyclovir. Ann Pharmacother 28:460–3
   PubMed Web of Science ®Google Scholar
• Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol 27:48–9
   PubMed Web of Science ®Google Scholar
• Koźbiał M, Gierycz P. (2013). Comparison of aqueous and 1-octanol solubility as well as liquid-liquid distribution of acyclovir derivatives and their complexes with Hydroxypropyl-β-Cyclodextrin. J Solution Chem 42:866–81
   PubMed Web of Science ®Google Scholar
• Laskin OL. (1983). Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet 8:187–201
   PubMed Web of Science ®Google Scholar
• Lin P, Torres G, Tyring SK. (2003). Changing paradigms in dermatology, antivirals in dermatology. Clin Dermatol 21:426–46
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME, Masson M. (2004). Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2:261–75
   Google Scholar
• Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85:1017–25
   PubMed Web of Science ®Google Scholar
• Loftsson T, Duchêne D. (2007). Cyclodextrins and their pharmaceutical applications. Int J Pharm 329:1–11
   PubMed Web of Science ®Google Scholar
• Luengo J, Aránguiz T, Sepúlveda J, et al. (2002). Preliminary pharmacokinetic study of different preparations of acyclovir with beta-cyclodextrin. J Pharm Sci 91:2593–8
   PubMed Web of Science ®Google Scholar
• Mukherjee B, Patra B, Layek B, Mukherjee A. (2007). Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study. Int J Nanomed 2:213–25
   PubMed Web of Science ®Google Scholar
• Mummidi V, Jayanthi V. (2013). Effect of hydrophilic polymers on isradipine complexation with hydroxypropyl β-cyclodextrin. Drug Dev Ind Pharm 39:970–7
   PubMed Web of Science ®Google Scholar
• Nasongkla N, Wiedmann AF, Bruening A, et al. (2003). Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. Pharm Res 20:1626–33
   PubMed Web of Science ®Google Scholar
• Paul S, Kumar A, Yedurkar P, Sawant K. (2013). Design and development of multiple emulsion for enhancement of oral bioavailability of acyclovir. Drug Dev Ind Pharm 39:1809--17
   Google Scholar
• Phillip Lee YH, Sathigari S, Jean Lin YJ, et al. (2009). Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. Drug Dev Ind Pharm 35:1113–20
   PubMed Web of Science ®Google Scholar
• Rossel CP, Carreño JS, Rodríguez-Baeza M, Alderete JB. (2000). Inclusion complex of the antiviral drug acyclovir with cyclodextrin in aqueous solution and in solid phase. Química Nova 23:749–52
   Web of Science ®Google Scholar
• Shah J, Vasanti S, Anroop B, Vyas H. (2009). Enhancement of dissolution rate of valdecoxib by solid dispersions technique with PVP K 30 & PEG 4000, preparation and in vitro evaluation. J Inclusion Phenom Macrocyclic Chem 63:219–24
   Google Scholar
• Spruance SL, Kriesel JD. (2002). Treatment of herpes simplex labialis. Herpes 9:64–9
   PubMedGoogle Scholar
• Spruance SL, Nett R, Marbury T, et al. (2002). Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 46:2238–43
   PubMed Web of Science ®Google Scholar
• Świerzewski R, Poznański J, Golankiewicz B, Zielenkiewicz W. (2002). NMR investigations of the stacking-like self-association of acyclovir, bromoacyclovir and ganciclovir. J Mol Liq 95:339–45
   Web of Science ®Google Scholar
• Taneri F, Ozcan I, Guneri T. (2010). In vitro and in vivo evaluation of oral tablet formulations prepared with ketoconazole and hydroxypropyl-beta-cyclodextrin. Drug Deliv 17:152–7
   PubMed Web of Science ®Google Scholar
• Tomar V, Garud N, Kannojia P, et al. (2010). Enhancement of solubility of acyclovir by solid dispersion and inclusion complexation methods. Der Pharmacia Lett 2:341–52
   Google Scholar
• Volpato NM, Santi P, Laureri C, Colombo P. (1997). Assay of acyclovir in human skin layers by high-performance liquid chromatography. J Pharm Biomed Anal 16:515–20
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Faulds D, Goa KL. (1994). Acyclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:153–205
   PubMed Web of Science ®Google Scholar
• Wang S, Ding Y, Yao Y. (2009). Inclusion complexes of fluorofenidone with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm 35:808–13
   PubMed Web of Science ®Google Scholar
• Zielenkiewicz W, Koźbiał M, Golankiewicz B, Poznański J. (2010). Enhancement of aqueous solubility of tricyclic acyclovir derivatives by their complexation with hydroxypropyl-β-cyclodextrin. J Therm Anal Calorim 101:555–60
   Web of Science ®Google Scholar